ADMA - ADMA Biologics, Inc.
| Previous Close | 4.96 |
| Open | 4.94 |
| Bid | 4.79 x 2200 |
| Ask | 0.00 x 900 |
| Day's Range | 4.93 - 5.10 |
| 52 Week Range | 2.01 - 5.70 |
| Volume | 157,754 |
| Avg. Volume | 181,562 |
| Market Cap | 225.021M |
| Beta | 2.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 |
| Earnings Date | May 10, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.88 |
- Benzinga•8 days ago
Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
- GlobeNewswire•9 days ago
ADMA Biologics Announces Closing of $40M Public Offering
RAMSEY, N.J. and BOCA RATON, Fla., June 12, 2018-- ADMA Biologics, Inc. announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a ...
- GlobeNewswire•13 days ago
ADMA Biologics Announces Pricing of Public Offering of Common Stock
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share, resulting in gross proceeds of approximately $40.0 million before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 12, 2018, subject to the satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to 1,255,230 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions. ADMA intends to use the net proceeds from this offering (i) for continued remediation and ongoing improvement and enhancements at its plasma fractionation facility located in Boca Raton, FL, (ii) to submit the Prior Approval Supplement for, and relaunch of, Bivigam®, (iii) to resubmit the Biologics License Application for its lead pipeline product candidate, RI-002, (iv) in connection with U.S. Food and Drug Administration approval of its third plasma collection facility, and (v) for general corporate purposes and other capital expenditures.
- GlobeNewswire•14 days ago
ADMA Biologics Announces Proposed Public Offering of Common Stock
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today that it has commenced an underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Raymond James & Associates, Inc. is acting as the sole book-running manager of the proposed offering.
- Zacks Small Cap Research•17 days ago
ADMA: Biotest Share Retirement Good for Shareholders
ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its first quarter 2018 financial results on May 14, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under its ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. The facility has been inspection-ready by the turn of the year and we await the arrival of the FDA inspection team.
- Simply Wall St.•last month
Who Owns Most Of ADMA Biologics Inc (NASDAQ:ADMA)?
Today, I will be analyzing ADMA Biologics Inc’s (NASDAQ:ADMA) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its shareRead More...
- ACCESSWIRE•last month
Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On May 16, 2018, the New Jersey-based biopharmaceutical Company announced that the United States Patent and Trademark Office has issued to ADMA US Patent No. 9,969,793 covering methods of treating respiratory infections. Active-Investors.com is currently working on the research report for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), which also belongs to the Healthcare sector as the Company ADMA Biologics.
- GlobeNewswire•last month
ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793 covering methods of treating respiratory infections. The newly issued patent encompasses methods of treating upper and lower respiratory infections, including those caused by Respiratory Syncytial Virus (“RSV”), other viruses, as well as bacteria utilizing ADMA’s investigational drug RI-002 that contains elevated, neutralizing antibody titers to RSV as well as elevated antibody titers to other respiratory pathogens, such as influenza virus, coronavirus, parainfluenza virus, and metapneumovirus. “The addition of this patent to ADMA’s immunoglobulin portfolio provides unique coverage for the therapeutic treatment of respiratory infections using our investigational drug RI-002,” stated Adam Grossman, President and CEO of ADMA.
- Associated Press•last month
Adma Biologics: 1Q Earnings Snapshot
The Ramsey, New Jersey-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs, came to 35 cents per share. The infectious disease drug developer posted revenue ...
- GlobeNewswire•last month
ADMA Biologics Reports First Quarter 2018 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018-- ADMA Biologics, Inc., today announced its financial results for the quarter ended March 31, 2018 and provided an update on its operations and corporate ...
- GlobeNewswire•last month
ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest
RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018-- ADMA Biologics, Inc. announced today that it has negotiated the receipt and immediate retirement of approximately 8.6 million shares of its non-voting ...
- Simply Wall St.•last month
Will ADMA Biologics Inc’s (NASDAQ:ADMA) Earnings Grow In The Next Couple Of Years?
The most recent earnings announcement ADMA Biologics Inc’s (NASDAQ:ADMA) released in December 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwindsRead More...
- GlobeNewswire•2 months ago
ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership
RAMSEY, N.J. and BOCA RATON, Fla., April 24, 2018-- ADMA Biologics, Inc., today announced that it has successfully completed the manufacturing, release and has made commercial sales of its first batch ...
- Simply Wall St.•3 months ago
ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?
Assessing ADMA Biologics Inc’s (NASDAQ:ADMA) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, whichRead More...
- Simply Wall St.•3 months ago
When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?
ADMA Biologics Inc’s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-based biologics for the treatment of immune deficiencies and infectious diseases. On 31 December 2017,Read More...
- Simply Wall St.•5 months ago
Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?
Leading ADMA Biologics Inc (NASDAQ:ADMA) as the CEO, Adam Grossman took the company to a valuation of $178.55M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- Simply Wall St.•6 months ago
Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?
Understanding ADMA Biologics Inc’s (NASDAQ:ADMA) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
- ACCESSWIRE•6 months ago
Wired News – ADMA Files Biologics License Application for Its Third Plasma Collection Center
Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA"), ...
- Capital Cube•7 months ago
ETFs with exposure to ADMA Biologics, Inc. : November 29, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Simply Wall St.•7 months ago
ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?
For ADMA Biologics Inc’s (NASDAQ:ADMA) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...
- Zacks Small Cap Research•7 months ago
ADMA: Third Quarter 2017 Financial Results and Corporate Update
By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ: ADMA) experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November ...
